Suzhou Pharma Services executive leadership is made up of industry professionals with decades of combined experience working for some of the most successful pharmaceutical enterprises in the world. At Suzhou Pharma Services, we have an international leadership team that is a perfect blend of Western influence and Chinese culture, focusing on delivering our customers a quality product at both the highest standards and attractive prices.
Partnering with Suzhou Pharma Services means having the security of knowing that your projects are in the care of experienced and knowledgeable industry veterans, directing a team of hardworking and dedicated professionals. Meet a few members of our Executive Management team below.
John W. Lowry, Chief Executive Officer
John Lowry was appointed CEO of Amerigen in 2010. Mr. Lowry has nearly 30 years of experience, most of which in leading product development organizations and global businesses in the pharmaceutical and medical device industries.
Most recently, Mr. Lowry was CEO of Catalent Pharma Solutions, a $1.7 billion leading provider of contract development, manufacturing and drug delivery technologies to global pharmaceutical and biotechnology customers. Prior to Catalent, he held several leadership positions for Cardinal Health, including Group President of Pharmaceutical Technologies and Services and President of R.P. Scherer. Mr. Lowry previously was President of Becton Dickinson’s Worldwide Diabetes Healthcare/Consumer Healthcare business and began his time at BD as Vice President of BD Medical Systems R&D.
Mr. Lowry spent the first 15 years of his career at GE, most recently at GE Healthcare. He holds a BSME from Villanova University.
Jack Wu, Chief Operating Officer
Jack Wu was appointed President of Suzhou Pharmaceuticals in 2011. Mr Wu has 20 years of experience in manufacturing operations management, with a particular focus on achieving operational excellence and building high performing teams. Prior to joining Suzhou Pharma, he served as Regional Manufacturing Director at Firmenich, where he managed four plants in Asia.
Jack was previously a Vice President of Manufacturing at Advanced Medical Optics (AMO), where he led the US Engineering Team and two FDA certified facilities in China and Spain. Earlier he was Director of Operations for Allergan’s plant in China, a US FDA and Australian TGA certified facility. Prior to AMO/Allergan, Jack held various plant management roles in China with GlaxoSmithKline.
Jack earned a BSc in pharmacy in China Pharmaceutical University and MBA in China Europe International Business School (CEIBS). He speaks fluent English and Mandarin.
Dennis M. Potter, Chief Financial Officer
Dennis Potter was appointed Chief Financial Officer for Amerigen in 2010. Mr. Potter has 30 years of experience, principally in the pharmaceutical industry, in finance, accounting, acquisitions, acquisition integration and pharmaceutical strategic alliances. Prior to joining Amerigen, he served as the Senior Vice President Finance and Administration and Chief Financial Officer for GeneraMedix Pharmaceuticals, a privately held generic injectables company.
Previously, Mr. Potter held senior positions in finance and strategic alliance management for Baxter Healthcare’s Anesthesia & Critical Care business unit. Prior to that, Mr. Potter held various finance positions at Ohmeda, and its parent company The BOC Group. Previously, Mr. Potter was an Audit Manager at Price Waterhouse.
Mr. Potter earned a Bachelor of Science in Accounting from the State University of New York at Binghamton, and is a certified public accountant.
Oliver Mueller, President
Oliver Mueller was appointed President of Suzhou Pharma Services in 2012. Mr. Mueller has nearly 30 years of pharmaceutical industry experience, most of which include the effective implementation of new business ventures, corporate leadership and business development.
In his most recent positions, Mr. Mueller served as Executive Vice-President, Business Development and Executive Vice President, Glatt Pharmaceutical Services Division for Glatt Air Techniques, Inc., a premier provider of process technology, equipment and contract services for the development and manufacture of solid dosage drug products. Previously, Mr. Mueller held numerous other leadership positions at Glatt, including Vice President, Technology Sales & Services and Executive Vice President, Nortec Development Associates, a generic drug product out-licensing affiliate.
Prior to that, Mr. Mueller held positions at The Procter & Gamble Manufacturing Company and Merck & Company, Inc. He holds a B.S. Chemical Engineering degree from Lafayette College.
Joanne B. Marriott, Senior Vice President, Quality Assurance
Joanne B. Marriott was appointed Senior Vice President of Quality for Amerigen in November, 2011. Ms. Marriott has over 35 years of experience in pharmaceutical Quality Assurance, Quality Control, Compliance and Regulatory Affairs with a focus on developing and maintaining quality systems in compliance with US FDA regulations. Ms. Marriott also has experience with international pharmaceutical regulations having served in expatiate capacities in Quality Assurance and Compliance in Latin America and Europe.
Prior to joining Amerigen, Ms. Marriott was Vice President of Regulatory Affairs with Catalent Pharma Solutions and had previously served as Vice President Quality Assurance and Regulatory Affairs for Cardinal Health’s Pharmaceutical Development segment of the Pharmaceutical Technology and Services business. Ms. Marriott also held positions at the Director level in both Quality Assurance and in Regulatory Affairs with Alcon Laboratories. She holds a BS in Biology and an MA in Management and is Regulatory Affairs Certified (RAC) by the Regulatory Affairs Professionals Society.
Jeff Parker, Director of Quality Control
Jeff Parker was appointed Director of Quality Control for Amerigen in 2011 Mr. Parker has 30 years of experience in the development, registration, and quality control of regulated products including pharmaceuticals and agrochemicals. Much of his career has been spent in international environments as he has worked for multinational companies based in the UK, Sweden, and France, as well as the USA. Mr. Parker is a native of North Carolina where he received his B.Sc. degree from East Carolina University and his A.S. degree from Mt. Olive College.
Rex Roberts, Director of Analytical Services
Rex Roberts was appointed Director of Technical Services for Amerigen in 2010 and appointed to his current position as Director of Analytical Services in 2011. He has over 25 years of experience in the pharmaceutical industry, during which time he has gained particular expertise in drug substance, drug product and container closure testing; analytical development, process development, manufacturing operations and validation. During his career, Dr. Roberts has spent significant time in both large pharma, medical device and contract services organizations. Dr. Roberts most recent responsibility was Director of Lab Operations for West Pharmaceutical Services directing the analytical services for R&D, plant operations and contract services organizations at West in the USA. Prior to that Dr. Roberts was Director of Pharmaceutical Sciences for Microbac Laboratories (CTO), Director of Technical Services for Catalytica (CMO) and Director of Technical Services for Burroughs Wellcome Co. Dr. Roberts has a Ph.D. in Physical Organic Chemistry from the University of Georgia, an A.B. in Chemistry from East Carolina University and was a postdoctoral fellow at Dartmouth College.
Weixuan He, Director of Analytical Services
Weixuan He was appointed Director of Analytical Services for Amerigen in 2011. Dr. He has more than 15 years of R&D experience working in the US pharmaceutical industry, with specific expertise in analytical and bioanalytical method development and validation.
Prior to joining Amerigen, Dr. He was associate director for analytical services at Meda Pharmaceuticals, where he was responsible for analytical methods development and validation to support new product development and manufacturing. Dr. He also held various technical positions at Bristol Myers Squibb and Entremed, with roles ranging from API synthesis, analytical and bioanalytical method development to the compilation of CMC documents in support of regulatory filings. Fluent in English and Mandarin, Dr. He obtained his PhD in Organic Chemistry from Oregon State University and a Post-Doctoral Fellowship at the Johns Hopkins University.